Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+Status

被引:16
|
作者
Lu, Hecheng [1 ,2 ]
Yin, Jiandong [2 ]
机构
[1] Northeastern Univ, Sch Med & Bioinformat Engn, Shenyang, Peoples R China
[2] China Med Univ, ShengJing Hosp, Dept Radiol, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
breast cancer; receiver operating characteristic; immunohistochemistry; magnetic resonance imaging; gene expression; IN-SITU HYBRIDIZATION; CONTRAST-ENHANCED MRI; NEOADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; MOLECULAR SUBTYPES; FEATURE-SELECTION; CANCER; HETEROGENEITY; EXPRESSION; FEATURES;
D O I
10.3389/fonc.2020.00543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast tumor heterogeneity is related to risk factors that lead to aggressive tumor growth; however, such heterogeneity has not been thoroughly investigated. Purpose: To evaluate the performance of texture features extracted from heterogeneity subregions on subtraction MRI images for identifying human epidermal growth factor receptor 2 (HER2) 2+ status of breast cancers. Materials and Methods: Seventy-six patients with HER2 2+ breast cancer who underwent dynamic contrast-enhanced magnetic resonance imaging were enrolled, including 42 HER2 positive and 34 negative cases confirmed by fluorescence in situ hybridization. The lesion area was delineated semi-automatically on the subtraction MRI images at the second, fourth, and sixth phases (P-1, P-2, and P-3). A regionalization method was used to segment the lesion area into three subregions (rapid, medium, and slow) according to peak arrival time of the contrast agent. We extracted 488 texture features from the whole lesion area and three subregions independently. Wrapper, least absolute shrinkage and selection operator (LASSO), and stepwise methods were used to identify the optimal feature subsets. Univariate analysis was performed as well as support vector machine (SVM) with a leave-one-out-based cross-validation method. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the performance of the classifiers. Results: In univariate analysis, the variance from medium subregion at P-2 was the best-performing feature for distinguishing HER2 2+ status (AUC = 0.836); for the whole lesion region, the variance at P-2 achieved the best performance (AUC = 0.798). There was no significant difference between the two methods (P = 0.271). In the machine learning with SVM, the best performance (AUC = 0.929) was achieved with LASSO from rapid subregion at P-2; for the whole region, the highest AUC value was 0.847 obtained at P-2 with LASSO. The difference was significant between the two methods (P = 0.021). Conclusion: The texture analysis of heterogeneity subregions based on intratumoral regionalization method showed potential value for recognizing HER2 2+ status in breast cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Assessment of HER2 Gene Status in Breast Carcinomas With Polysomy of Chromosome 17
    Vranic, Semir
    Teruya, Bryan
    Repertinger, Susan
    Ulmer, Pamela
    Hagenkord, Jill
    Gatalica, Zoran
    CANCER, 2011, 117 (01) : 48 - 53
  • [42] Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
    Penault-Llorca, Frederique
    Vincent-Salomon, Anne
    Bellocq, Jean-Pierre
    Matthieu, Marie-Christine
    Grogan, Gaetan-Mac
    Treilleux, Isabelle
    Ettore, Francette
    Laberge-Le Couteulx, Sophie
    Sigal, Brigitte
    Couturier, Jerome
    Lacroix-Triki, Magali
    Antoine, Martine
    Balaton, Andre
    Baranzelli, Marie-Christine
    Becette, Valerie
    Blanc-Fournier, Cecile
    Bibeau, Frederic
    Brabencova, Eva
    Croce, Sabrina
    Fridman, Viviana
    Genin, Pascal
    Ghnassia, Jean-Pierre
    Jacquemier, Jocelyne
    Poulet, Bruno
    Roger, Pascal
    Sagan, Christine
    Tas, Patrick
    Trassard, Martine
    Verriele, Veronique
    Arnould, Laurent
    ANNALES DE PATHOLOGIE, 2010, 30 (05) : 357 - 373
  • [43] Radiomics analysis of intratumoral and different peritumoral regions from multiparametric MRI for evaluating HER2 status of breast cancer: A comparative study
    Zhou, Jing
    Yu, Xuan
    Wu, Qingxia
    Wu, Yaping
    Fu, Cong
    Wang, Yunxia
    Hai, Menglu
    Tan, Hongna
    Wang, Meiyun
    HELIYON, 2024, 10 (07)
  • [44] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [45] Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer
    Zhou, Jing
    Tan, Hongna
    Li, Wei
    Liu, Zehua
    Wu, Yaping
    Bai, Yan
    Fu, Fangfang
    Jia, Xin
    Feng, Aozi
    Liu, Huan
    Wang, Meiyun
    ACADEMIC RADIOLOGY, 2021, 28 (10) : 1352 - 1360
  • [46] A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity
    Nishida, Yasunori
    Kuwata, Takeshi
    Nitta, Hiroaki
    Dennis, Eslie
    Aizawa, Masaki
    Kinoshita, Takahiro
    Ohtsu, Atsushi
    Ochiai, Atsushi
    GASTRIC CANCER, 2015, 18 (03) : 458 - 466
  • [47] Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
    Seol, Hyesil
    Lee, Hyun Ju
    Choi, Yoomi
    Lee, Hee Eun
    Kim, Yu Jung
    Kim, Jee Hyun
    Kang, Eunyoung
    Kim, Sung-Won
    Park, So Yeon
    MODERN PATHOLOGY, 2012, 25 (07) : 938 - 948
  • [48] Intratumoral heterogeneity of HER2/neu in breast cancer -: A rare event
    Hanna, Wedad
    Nofech-Mozes, Sharon
    Kahn, Harriette J.
    BREAST JOURNAL, 2007, 13 (02): : 122 - 129
  • [49] HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas
    Shen, Tiansheng
    Nitta, Hiroaki
    Wei, Lai
    Parwani, Anil, V
    Li, Zaibo
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (03) : 519 - 527
  • [50] A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
    Guo, Qianqian
    Chen, Kai
    Lin, Xiaojie
    Su, Yi
    Xu, Rui
    Dai, Yan
    Qiu, Chang
    Song, Xue
    Mao, Siying
    Chen, Qianjun
    ONCOTARGET, 2017, 8 (55) : 93492 - 93501